Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

A groundbreaking study has revealed that GLP-1 receptor agonists—including popular weight-loss and diabetes drugs like ...

A woman on Ozempic has revealed why she gave her 11 year old daughter weight loss jabs, a similar drug called Wegovy, on This Morning ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Lawmakers are trying to restore access to GLP-1 weight loss drugs, like Ozempic and Wegovy, after Ohio removed medical ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Wegovy launched here is to support Singapore’s efforts in improving population health: Novo Nordisk Read more at straitstimes ...